Latest News

Why most eligible lymphoma patients miss CAR T: experts urge stronger academic-community handoffs, clearer protocols, and smarter caregiver support.

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

How to manage Richter transformation: rapid biopsy, targeted combos, and early referral for CAR T or transplant—closing the access gap.

FDA grants orphan drug designation to HCB101 for gastric cancer; early trials suggest safer CD47 checkpoint blockade with promising tumor control in advanced settings.

ASH updates AYA ALL care: pediatric-inspired frontline therapy, MRD-driven decisions, targeted TKIs, and immunotherapy-led relapse treatment.

BTK inhibitors or time-limited venetoclax combos? Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life.

Nivolumab–ipilimumab extends survival in unresectable HCC, but US cost-effectiveness falls short; dosing changes or price cuts may shift value.

Dr Manmeet Ahluwalia explores how precision oncology and targeted therapies are transforming brain metastases care, extending survival from months to years.

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS following transplant.

Cabozantinib plus temozolomide led to favorable short-term progression-free survival in a single-arm trial of patients with advanced leiomyosarcoma.

FDA accepts Ameluz PDT sNDA for superficial basal cell carcinoma, with strong phase 3 clearance data and a September 2026 decision deadline.

FDA approves Optune Pax, a wearable tumor treating fields device, to pair with GnP chemo in locally advanced pancreatic cancer, extending survival and delaying pain.

G6PD deficiency links to higher remission and longer survival in AML patients on venetoclax plus azacitidine, suggesting a simple biomarker to guide treatment.

Global phase 3 trial tests safusidenib maintenance after chemoradiotherapy, aiming to delay recurrence and improve survival in IDH1-mutant astrocytoma.

FDA fast-tracks irpagratinib for FGF19+ advanced liver cancer, with early trials showing strong response rates and ongoing combo study momentum.

A recent white paper determines that the link between GLP-1 agonist inhibitors and thyroid cancer is unconvincing.

FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable safety.

Brittany Dulmage, MD, discusses why a popular ingredient in hair, skin, and nails vitamins may not be a safe option for patients undergoing cancer treatment.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.

Final MOUNTAINEER data show tucatinib plus trastuzumab delivers durable responses and manageable safety in HER2+ RAS wild-type metastatic colorectal cancer.

NPX372 received Investigational New Drug Clearance from the FDA, allowing for clinical development.

In an interview, Saad Z. Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated multiple myeloma.

New research defines distinct therapeutic strategies for the 2 classes of CALR mutations in myelofibrosis, with implications for future patient management and clinical trial design.

SEER-Medicare data show just 4% of older adults with blood cancers enter clinical trials, revealing disparities and fixable access barriers.

At 33.6 months' follow-up, patients with standard-risk multiple myeloma had improved progression-free survival outcomes with cilta-cel vs standard-of-care.

A retrospective study of tumor-infiltrating lymphocyte therapy showed that despite its benefit, many patients were unable to receive lifileucel.

Phase 1 data show EB103 delivers 100% complete responses at high dose with manageable toxicity, offering a safer, durable option for high-risk B-cell NHL.

Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.

FDA lifts Yescarta limits for relapsed primary CNS lymphoma, expanding CAR T access with phase 1 safety data—what to know about neuro risks.